A Multicentre, Open Label, Nonrandomised, Non- Interventional, A Multicentre, Open Label, Nonrandomised, Non- Interventional, Observational Study to Evaluate the Quality of Life and Clinical Outcomes in Subjects Using Biphasic Insulin Aspart 30 (NovoMix 30) for the Treatment of Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms IMPROVE-Life
- Sponsors Novo Nordisk
- 24 May 2012 Official Title amended as reported by ClinicalTrials.gov.
- 16 Oct 2009 Actual patient number changed from 13707 to 23684 added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Actual patient number (13707) added as reported by ClinicalTrials.gov.